医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

RMK Launches Color Blind Glasses ‘Dalton’

2023年10月31日 PM10:00
このエントリーをはてなブックマークに追加


 

SEJONG, South Korea

RMK Inc., established as a venture company for the colorblind, launched “Dalton,” a sunglass designed for color blindness correction.

Dalton comes with a colorblindness correction lens developed as the first in Korea using advanced optical technology. Its registration for a domestic patent was completed (Registration No. 2113775), and international patents have also been applied for in the U.S., Europe, and China.

According to the Ministry of Health and Welfare in South Korea, as many as approximately 1.65 million people in Korea suffer from color weakness or blindness.

Launched to relieve the inconvenience of the colorblind, Dalton sunglasses block the harmful UV rays and short blue wavelength (410 nm and less) by 100%, and lower the transmittance of green wavelength (520-540 nm) down to 3% to provide the color correction effect. In addition, the lens itself consists of seven layers, ensuring the visual comfort of the users.

Dalton of RMK, the colorblindness correction glasses, was developed by a researcher for his colorblind child. Minki Ryu, CEO of RMK and, the developer of Dalton, said, “I made this product hoping that everyone can enjoy seeing a wide range of colors clearly.”

Dalton sunglasses with 99% UV protection effect are not for medical use and therefore can be worn by general customers. Emphasizing blue, red, and yellow colors excluding green from the color spectrum, the product allows users to have a special experience.

To learn more about RMK and Dalton, please visit: http://www.rmkinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031967355/en/

CONTACT

EDL ENTERPRISE for RMK

Sujin Lee

lsj@edl.co.kr

TimeLine:

同じカテゴリーの記事 

  • Heuron Gets FDA Green Light for Stroke Triage and Notification Solution
  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
  • Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
  • Otsuka to Terminate Development of AVP-786